GLMD
Galmed Pharmaceuticals Ltd.Company with tickers: GLMD
CIK
1595353
CUSIP
M47238148
Shares Outstanding
6,581,390
Website
https://galmedpharma.com
Investor Relations
https://galmedpharma.com/investors/
13F Activity (30d)
2 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $8,510,000 | USD | 2025-12-31 | 20-F | 2026-03-31 |
| Research & Development | $990,000 | USD | 2025-12-31 | 20-F | 2026-03-31 |
| Operating Income | — | ||||
| Net Income | $-10,309,000 | USD | 2025-12-31 | 20-F | 2026-03-31 |
| EPS (Basic) | $2.39 | USD/shares | 2025-12-31 | 20-F | 2026-03-31 |
| EPS (Diluted) | $2.39 | USD/shares | 2025-12-31 | 20-F | 2026-03-31 |